SCHEMBL6821050

SCHEMBL6821050

CC(C)n1cnc2c(NCc3cccc(Cl)c3)nc(Cl)nc21

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK1 P06493 7/20 0.79
CDK2 P24941 1/20 0.68
CDK9 P50750 1/20 0.68
KDM4E B2RXH2 1/20 0.61
NPC1 O15118 1/20 0.61
MAPT P10636 1/20 0.61
TDP1 Q9NUW8 1/20 0.61
ADORA3 P0DMS8 4/20 0.61
ADORA2A P29274 3/20 0.61
ADORA1 P30542 2/20 0.61
TMIGD3 P0DMS9 1/20 0.61
HTR2C P28335 1/20 0.61
HTR2B P41595 1/20 0.61
HTR3A P46098 1/20 0.61
CDK5 Q00535 1/20 0.60
PPARD Q03181 4/20 0.57
CCNB2 O95067 2/20 0.56
CCNB1 P14635 2/20 0.56
CCNB3 Q8WWL7 2/20 0.56
PDE2A O00408 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31072387 0.90 CDK1 (0.78) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL1443862 0.89 CDK1 (0.76) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL6820864 0.89 CDK1 (0.76) CDK1KDM4ENPC1MAPTTDP1
SCHEMBL28771300 0.89 CDK1 (0.76) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL28457283 0.89 CDK1 (0.76) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL3295975 0.89 CDK2 (0.66) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL1400442 0.89 CDK1 (1.00) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL1443458 0.87 CDK1 (0.80) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL17628586 0.86 CDK1 (0.80) CDK1CDK2CDK9KDM4ENPC1
SCHEMBL6152647 0.86 CDK1 (0.82) CDK1CDK2KDM4ENPC1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1056745-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2004-06-16 EP disclosed
US-6413974-B1 INHIBITORS OF CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; PREVENTING APOPTOSIS IN NEURONAL CELLS; ANTINEOPLASTIC AGENTS; NEURONAL INJURY AND DEGENERATION; CEREBROVASCULAR DISEASE AVENTIS PHARMACEUTICALS INC. 2002-07-02 US disclosed
EP-1056745-A2 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 EP disclosed
WO-1999043676-A2 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 WO disclosed